Two-dose SARS-CoV-2 vaccine effectiveness in British Columbia (BC), Canada

Summary: In this presentation, the effectiveness of two doses of SARS-CoV-2 vaccine in BC will be presented by outcome (including infection and hospitalization), vaccine type (including "mix and match"), age group (including elderly adults), variant of concern (including Delta), duration since vaccination, and finally interval between doses to assess the impact on booster dose protection associated with second-dose deferral in Canada. Presenter: Dr. Danuta Skowronski leads the Influenza and Emerging Respiratory Pathogens Team at the British Columbia Centre for Disease Control (BCCDC) where she informs surveillance, research and program/policy recommendations for influenza, and more recently COVID-19. With more than 170 scientific publications, Dr. Skowronski is credited with pioneering development of the test-negative design, a methodology now used globally for seasonal influenza and COVID-19 vaccine effectiveness monitoring. She will share observations of two-dose COVID-19 vaccine effectiveness in BC.

BC CDC Presenters

9/28/2021 7:00:00 PM